Physician profile
Deric Savior
NPI 1912183765
$343,317.14
in general payments reported to CMS, 2019-2025
81 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $29K · 2021: $68K · 2022: $37K · 2023: $52K · 2024: $52K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Consulting Fee: $34K · Food and Beverage: $18K · Travel and Lodging: $11K · Honoraria: $3,600 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,119.21 |
| Consulting Fee | $33,793.75 |
| Food and Beverage | $17,568.16 |
| Travel and Lodging | $11,478.80 |
| Honoraria | $3,600.00 |
| Education | $196.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $122,762.33 | 2019-2025 | Libtayo |
| Genzyme Corporation | $68,205.74 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $67,988.16 | 2021-2025 | Zepzelca |
| Janssen Biotech, INC. | $24,577.55 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Celgene Corporation | $15,726.94 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $5,598.59 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,405.98 | 2022-2025 | Gilotrif |
| Regeneron Pharmaceuticals, INC. | $3,987.05 | 2023-2024 | Libtayo |
| Fosun Pharma USA INC. | $3,820.09 | 2024 | Serplulimab |
| Astrazeneca Pharmaceuticals Lp | $3,405.10 | 2020-2025 | Enhertu, Imfinzi, Calquence |
| Eli Lilly and Company | $2,925.00 | 2021 | |
| Emd Serono, INC. | $2,220.35 | 2023-2025 | |
| Blueprint Medicines Corporation | $2,122.80 | 2020-2024 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $1,977.84 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,966.70 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $990.56 | 2022-2025 | |
| Astellas Pharma US INC | $757.58 | 2020-2025 | Padcev, Xtandi, Xospata |
| Merck Sharp & Dohme LLC | $711.03 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $581.24 | 2022-2025 | Verzenio |
| Seagen INC. | $540.70 | 2021-2023 | Padcev, Adcetris |
| Genentech USA, INC. | $459.59 | 2019-2025 | Venclexta, Polivy, Itovebi |
| Eisai INC. | $455.80 | 2022-2025 | |
| Incyte Corporation | $404.78 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $374.05 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $364.48 | 2021-2025 | Enhertu, Vanflyta, Datroway |
| Gilead Sciences, INC. | $292.60 | 2023-2025 | Trodelvy |
| Pfizer INC. | $269.12 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $256.39 | 2023-2025 | Ultomiris |
| Boston Scientific Corporation | $247.75 | 2025 | Therasphere Administration Set |
| Dendreon Pharmaceuticals LLC | $224.22 | 2024 | Provenge |
| Caris Mpi, INC. | $204.31 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $199.36 | 2022-2025 | Onivyde, Somatuline Depot |
| Abbvie INC. | $190.88 | 2024-2025 | |
| Exelixis INC. | $176.22 | 2023-2025 | Cabometyx |
| Tempus Ai, INC | $170.53 | 2024-2025 | Xt Cdx |
| Kite Pharma, INC. | $156.94 | 2023-2025 | Yescarta |
| Genmab U.S., INC. | $139.42 | 2023-2025 | Epkinly, Tivdak |
| Array Biopharma INC | $121.50 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Beigene USA, INC. | $119.72 | 2023-2025 | Brukinsa, Tevimbra |
| Beone Medicines USA, INC. | $117.15 | 2025 | Brukinsa, Tevimbra |
| Sobi, INC | $115.02 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $109.82 | 2022-2025 | Monoferric |
| Acrotech Biopharma INC. | $107.91 | 2022-2025 | Beleodaq |
| Tersera Therapeutics LLC | $99.98 | 2023-2025 | Zoladex, Quzyttir |
| Taiho Oncology, INC. | $95.43 | 2022-2025 | |
| Pharmaessentia USA Corporation | $93.44 | 2023-2025 | Besremi |
| Puma Biotechnology, INC. | $92.81 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $90.23 | 2022-2024 | Xpovio |
| Amgen INC. | $89.52 | 2022-2024 | Vectibix, Blincyto, Xgeva |
| Stemline Therapeutics INC. | $86.39 | 2023-2025 | Orserdu |
| Mirati Therapeutics, INC. | $78.89 | 2023 | Krazati |
| Morphosys, US INC. | $74.57 | 2022-2023 | Monjuvi |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Novocure INC. | $65.88 | 2024-2025 | Optune Lua (Novottf-200t) |
| Aveo Pharmaceuticals, INC. | $63.88 | 2022-2025 | |
| Immunogen, INC. | $59.79 | 2023-2024 | Elahere, Elahere |
| Legend Biotech USA INC. | $55.17 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $53.61 | 2022-2024 | Tavalisse, Rezlidhia |
| Deciphera Pharmaceuticals INC. | $51.37 | 2022-2024 | Qinlock |
| Sumitomo Pharma America, INC. | $50.74 | 2023-2025 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $45.18 | 2023 | Empaveli |
| Immunocore Limited | $37.51 | 2024 | Kimmtrak |
| Cumberland Pharmaceuticals, INC. | $33.35 | 2024 | Sancuso |
| Adaptive Biotechnologies Corporation | $33.03 | 2022-2023 | Clonoseq |
| Organon LLC | $32.00 | 2023 | Ontruzant |
| Alnylam Pharmaceuticals INC. | $29.19 | 2023 | Givlaari |
| Heron Therapeutics, INC. | $26.99 | 2022 | |
| Servier Pharmaceuticals LLC | $26.41 | 2025 | |
| Foundation Medicine, INC. | $25.55 | 2023 | |
| Biogen, INC. | $24.16 | 2021 | |
| G1 Therapeutics, INC. | $23.56 | 2023 | Cosela |
| Fennec Pharmaceuticals, INC. | $23.04 | 2024 | Pedmark |
| Adc Therapeutics America, INC. | $20.08 | 2025 | |
| Fresenius Kabi USA, LLC | $19.73 | 2023 | Stimufend |
| Progenics Pharmaceuticals, INC. | $19.67 | 2025 | |
| Myovant Sciences INC. | $19.49 | 2022 | |
| Epizyme, INC. | $16.35 | 2022 | |
| Secura Bio, INC. | $14.53 | 2024 | Copiktra |
| Coherus Oncology, INC. | $13.65 | 2024 | |
| Global Blood Therapeutics, INC. | $13.09 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deric Savior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.